Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab adizutecan plus FOLFOX versus modified FOLFIRINOX for first-line metastatic pancreatic ductal adenocarcinoma
MOH_2026-04-26_015789Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telisotuzumab adizutecan in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by AbbVie Inc. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2026-04-26_015789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-26_015789.